<DOC>
	<DOC>NCT00116441</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.</brief_summary>
	<brief_title>Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>De novo multiple myeloma ECOG 02 No serious comorbid illnesses and adequate organ function &gt; 4 weeks from systemic steroids No existing secondary malignancies and no history of secondary malignancies in the past 5 years No active autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cancer</keyword>
	<keyword>PSCT</keyword>
	<keyword>Peripheral Stem Cell Transplant</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>GVAX</keyword>
</DOC>